DCAF17 Inhibitors

DCAF17 inhibitors represent a class of small molecules that specifically target the DDB1 and Cullin 4-associated factor 17 (DCAF17) protein. DCAF17 is a substrate receptor within the Cullin 4-RING E3 ubiquitin ligase (CRL4) complex, which plays a pivotal role in the ubiquitin-proteasome pathway, a central mechanism for the regulated degradation of intracellular proteins. The primary function of DCAF17 within this complex is to recognize and facilitate the ubiquitination and subsequent degradation of specific target proteins by the proteasome. DCAF17 inhibitors are designed to modulate the activity of DCAF17, thereby influencing its interactions with target substrates and ultimately affecting their stability within the cell.

The mechanism of action of DCAF17 inhibitors typically involves binding to DCAF17 or its associated protein partners, altering the formation or activity of the CRL4 E3 ubiquitin ligase complex. By doing so, these inhibitors can disrupt the ubiquitination and degradation of particular proteins targeted by DCAF17. This interference can have far-reaching consequences on cellular processes, as the stability of numerous regulatory proteins is reliant on DCAF17-mediated ubiquitination. Researchers have identified various DCAF17 inhibitors, some of which are derivatives of thalidomide, lenalidomide, or pomalidomide, each exhibiting different levels of specificity and potency in modulating the activity of DCAF17 within the CRL4 complex. The development and refinement of these inhibitors have provided valuable insights into the ubiquitin-proteasome system, shedding light on the intricate regulatory networks governing protein turnover and degradation within the cell.